Ultragenyx Pharmaceutical Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
547.60 |
652.34 |
825.84 |
1,241.17 |
1,715.11 |
2,412.86 |
| Przychód Δ r/r |
0.00% |
19.13% |
26.60% |
50.29% |
38.18% |
40.68% |
| Przychód (min) |
537.79 |
650.32 |
666.94 |
1,218.32 |
1,537.28 |
2,162.68 |
| Przychód (max) |
557.11 |
654.38 |
1,021.66 |
1,264.02 |
1,888.98 |
2,657.47 |
| EBITDA (średnia) |
-476.74 |
-567.93 |
-718.98 |
-1,080.56 |
-1,493.17 |
-2,100.63 |
| EBIT (średnia) |
-488.64 |
-582.10 |
-736.93 |
-1,107.54 |
-1,530.45 |
-2,153.08 |
| EBIT % |
-89.23% |
-89.23% |
-89.23% |
-89.23% |
-89.23% |
-89.23% |
| Zysk netto (średni) |
-549.58 |
-477.43 |
-394.13 |
-104.47 |
259.73 |
658.47 |
| Zysk netto % |
-100.36% |
-73.19% |
-47.72% |
-8.42% |
15.14% |
27.29% |
| EPS (średnia) |
-6.19 |
-5.27 |
-3.74 |
-0.95 |
2.87 |
7.27 |
| Liczba analityków (Przychody) |
12 |
12 |
20 |
15 |
6 |
11 |
| Liczba analityków (EPS) |
13 |
11 |
15 |
11 |
5 |
4 |
| symbol |
RARE |
RARE |
RARE |
RARE |
RARE |
RARE |